https://www.selleckchem.com/pr....oducts/pyridostatin-
Direct-acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection. To evaluate the clinical effectiveness of DAA in a safety-net population. Retrospective cohort study including patients who received at least one dose of DAA for chronic HCV infection. Primary outcome was sustained virologic response (SVR) defined as undetectable viral load at least 12 weeks after treatment termination. Notable patient (n=174) characteristics included 58% racial/ethnic minority group
Like
Comment
Share
